Diverse applications of nanomedicine

B Pelaz, C Alexiou, RA Alvarez-Puebla, F Alves… - ACS …, 2017‏ - ACS Publications
The design and use of materials in the nanoscale size range for addressing medical and
health-related issues continues to receive increasing interest. Research in nanomedicine …

Combinational strategy for high-performance cancer chemotherapy

SY Qin, YJ Cheng, Q Lei, AQ Zhang, XZ Zhang - Biomaterials, 2018‏ - Elsevier
The clinical outcomes of conventional mono-chemotherapy of cancers are usually far from
satisfactory due to some issues such as tumor heterogeneity and resistance to …

Supramolecular “Trojan Horse” for nuclear delivery of dual anticancer drugs

Y Cai, H Shen, J Zhan, M Lin, L Dai… - Journal of the …, 2017‏ - ACS Publications
Nuclear delivery and accumulation are very important for many anticancer drugs that interact
with DNA or its associated enzymes in the nucleus. However, it is very difficult for neutrally …

CSF1R‐and SHP2‐inhibitor‐loaded nanoparticles enhance cytotoxic activity and phagocytosis in tumor‐associated macrophages

A Ramesh, S Kumar, D Nandi, A Kulkarni - Advanced Materials, 2019‏ - Wiley Online Library
Immune modulation of macrophages has emerged as an attractive approach for anti‐cancer
therapy. However, there are two main challenges in successfully utilizing macrophages for …

A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer

A Kulkarni, V Chandrasekar, SK Natarajan… - Nature biomedical …, 2018‏ - nature.com
Effectively activating macrophages that can 'eat'cancer cells is challenging. In particular,
cancer cells secrete macrophage colony stimulating factor (MCSF), which polarizes tumour …

Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-κB inhibitor for antitumor immunotherapy

Z **ao, Z Su, S Han, J Huang, L Lin, X Shuai - Science advances, 2020‏ - science.org
The response to programmed cell death protein-1 (PD-1)/programmed death ligand-1 (PD-
L1) blockade in cancer immunotherapy is limited because of multiple immune evasion …

Drug combination synergy in worm-like polymeric micelles improves treatment outcome for small cell and non-small cell lung cancer

X Wan, Y Min, H Bludau, A Keith, SS Sheiko… - ACS …, 2018‏ - ACS Publications
Nanoparticle-based systems for concurrent delivery of multiple drugs can improve outcomes
of cancer treatments, but face challenges because of differential solubility and fairly low …

Engineering nanoparticles-enabled tumor-associated macrophages repolarization and phagocytosis restoration for enhanced cancer immunotherapy

Y Gong, W Gao, J Zhang, X Dong, D Zhu… - Journal of …, 2024‏ - Springer
Tumor-associated macrophages (TAMs) are pivotal within the immunosuppressive tumor
microenvironment (TME), and recently, have attracted intensive attention for cancer …

Engineering nanoparticles for cancer immunotherapy: Current achievements, key considerations and future perspectives

MU Farooq, CH Lawrie, NN Deng - Chemical Engineering Journal, 2024‏ - Elsevier
Cancer immunotherapies, which rely on training or stimulating our immune system, are
revolutionizing the way of cancer treatment. In recent years, these revolutionary weapons …

Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy

A Ramesh, A Brouillard, S Kumar, D Nandi, A Kulkarni - Biomaterials, 2020‏ - Elsevier
Among the numerous immune interactions, or lack-thereof, that occur during cancer
progression, tumor-associated macrophages (TAMs)–cancer cell interactions have been …